Nasdaq-listed Sonnet BioTherapeutics agrees to $888 million merger to become Hyperliquid Strategies, launch HYPE treasury
-
最新报道：Nasdaq-listed Sonnet BioTherapeutics will merge with Rorschach I LLC to form Hyperliquid Strategies, Inc., creating a public crypto treasury company holding 12.6 million HYPE tokens and $305 million cash (total value $888 million). Paradigm's Matt Huang praised Hyperliquid's fundamentals and institutional demand, while Atlas' Bob Diamond will chair the new entity. The firm plans to acquire more HYPE tokens, leveraging Hyperliquid's $1.5T annual trading volume. Sonnet shareholders will receive contingent value rights as the biotech firm becomes a subsidiary, with its shares surging 300% pre-market. Strategic investors include Paradigm, Galaxy Digital, and Pantera Capital.
下一篇
Ripple (XRP) and Sui (SUI) Surge Toward All-Time Highs: Price Analysis
- While Bitcoin (BTC) is still maintaining its latest surge, the altcoins are starting to ma...
24小时热点
热点专题
407106